Warner Chilcott

18 total trials 18 completed

Trial Pipeline

COMPLETED Phase 2

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

NCT02670785

COMPLETED Phase 3

Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)

NCT01455597

COMPLETED Phase 3

Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women

NCT01400776

COMPLETED Phase 3

Treatment of Erectile Dysfunction II

NCT01037218

COMPLETED Phase 3

Treatment of Erectile Dysfunction I

NCT01037244

COMPLETED Phase 2

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

NCT00918749

COMPLETED Phase 1

Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

NCT00699777

COMPLETED Phase 3

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

NCT00541658

COMPLETED

Fecal Biomarker Study for Patients With Ulcerative Colitis

NCT00780507

COMPLETED Phase 3

A Comparison of Once a Day Dose Compared to 2 Doses/Day

NCT00505778

COMPLETED Phase 3

Study of Safety and Efficacy of an Oral Contraceptive

NCT00477633

COMPLETED Phase 2

Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate

NCT00577720

COMPLETED Phase 3

A Study of Monthly Risedronate for Osteoporosis

NCT00247273

COMPLETED Phase 3

Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

NCT00106028

COMPLETED Phase 2

Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

NCT00577837

COMPLETED

Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate

NCT00778154

COMPLETED Phase 1

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

NCT00577850

COMPLETED Phase 3

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00349791

What the Pipeline for Warner Chilcott Shows

According to the ClinicalTrials.gov registry, Warner Chilcott is linked to 18 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 18 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Warner Chilcott reports 10 late-stage studies (Phase 3 and Phase 4 combined) and 6 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Warner Chilcott is Postmenopausal Osteoporosis with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial